Balt Resolves $1.2 FCPA Enforcement Action

Key Takeaways

• $1.2M FCPA settlement for French medical device firm
• Bribes to state hospital physician deemed foreign official
• Self‑disclosure and cooperation avoided criminal prosecution
• First corporate resolution under DOJ’s new CEP policy
• Indictments target two executives for same scheme

Summary

The U.S. Department of Justice resolved a $1.2 million Foreign Corrupt Practices Act enforcement action against Balt SAS, a French medical‑device company. The DOJ determined Balt paid roughly $602,000 in bribes to a senior physician at a state‑owned French hospital, treating the physician as a “foreign official” under the FCPA. Balt avoided prosecution by voluntarily self‑disclosing, fully cooperating, and implementing remediation, resulting in a decline of prosecution under the Department‑wide Corporate Enforcement Policy. Separate criminal indictments were filed against two individuals, David Ferrera and Marc Tilman, for their role in the scheme.

Pulse Analysis

The Foreign Corrupt Practices Act has long targeted illicit payments to foreign government officials, but its definition of a "foreign official" continues to evolve. Recent DOJ guidance treats senior physicians at state‑owned hospitals as officials, a move that expands the law’s reach into the health‑care sector. Companies that sell medical devices abroad must now scrutinize relationships with public‑sector clinicians, as even seemingly routine consulting fees can trigger FCPA liability if the recipient wields influence over procurement decisions.

Balt SAS’s $1.2 million resolution illustrates how the Department of Justice is applying the new Corporate Enforcement Policy (CEP). By voluntarily reporting the misconduct, providing full cooperation, and swiftly remediating internal controls, Balt secured a decline of prosecution despite a $602,000 bribery scheme that generated over $1.6 million in revenue. The CEP rewards timely self‑disclosure and robust remediation, signaling to multinational firms that transparent internal investigations can mitigate penalties and preserve corporate reputation.

For the broader medical‑device industry, the Balt case serves as a cautionary tale and a roadmap. Executives should embed rigorous vetting of third‑party consultants, enforce strict invoice verification, and train senior staff on the expanded foreign‑official definition. Aligning compliance programs with both U.S. and local French enforcement expectations will become essential, as coordinated investigations between the DOJ and French authorities are now commonplace. Proactive governance not only reduces legal exposure but also strengthens stakeholder confidence in a market where ethical procurement is increasingly scrutinized.